LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.

ABSTRACT: LIM domain binding protein 2 (LDB2), a transcriptional co-regulator of the LIM protein family, is reported to be downregulated in various tumors. However, its role in bladder cancer (BLCA) remains undefined. This study analyzed the molecular mechanism of LDB2 in inhibiting the metastasis of bladder cancer and its diagnostic and prognostic value in BLCA. We integrated The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets with enrichment analysis to evaluate the expression, diagnostic potential, and prognostic significance of LDB2 in BLCA. Immunohistochemistry (IHC) was performed to assess LDB2 expression in normal and metastatic tissues and its correlation with clinical stage and prognosis. Functional assays, including clonogenic and Transwell assays, were conducted in L

SUBMITTER: Li Y 

PROVIDER: S-EPMC12628452 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature